COVID-19: An Update with Dr. Mark Burns
Dr. Mark Burns gives an update on COVID-19 by first discussing its history and epidemiology. He then describes the lifecycle of Sars-CoV-2 and the events surrounding the Cytokine Storm. After, he explains the clinical presentation and current commendations for pharmacologic management and finally, the vaccines in phase 3 trials.
Watch on YouTube
Listen as a Podcast
Watch more lectures about Infectious Diseases
Mark Burns, M.D.
Dr. Mark Burns is an Assistant Professor of Medicine at the University of Louisville. His clinical expertise is in Infectious Diseases and he is board certified on the American Board of Internal Medicine - Infectious Diseases. Dr. Burns attended the University of Louisville for Medical School, completed his residency at the University of Louisville Hospital, and his fellowship at the University of Louisville. Learn more here.
Dr. Forest Arnold returns to discuss co-infections in COVID-19 by first presenting case reports and pathophysiology. After, he explains etiology and frequency and finally, diagnosis and treatment.
Dr. Forest Arnold returns to present "COVID-19 Vaccines: Wows and Woes" today on Louisville Lectures. In this presentation, Dr. Arnold gives an overview of COVID-19 and vaccines. He then discusses a case of potential thrombosis due to the Johnson & Johnson vaccine as well as the pathophysiology of vaccine-induced immune thrombotic thrombocytopenia (VITT). After, he presents the CDC Advisory Committee on Immunization Practices and the efficacy of vaccines in light of variants. And finally, Dr. Arnold discusses post acute COVID-19 Syndrome (PACS).
Dr. Mark Burns gives an update on COVID-19 by first discussing its history and epidemiology. He then describes the lifecycle of Sars-CoV-2 and the events surrounding the Cytokine Storm. After, he explains the clinical presentation and current commendations for pharmacologic management and finally, the vaccines in phase 3 trials.
Dr. Forest Arnold's focuses on summarizing the extent of human coronaviruses, risk factors, and the clinical presentation of patients with coronavirus to the extent known. He then identifies the current infection prevention and control approach, as well as clinical management and future directions.
Dr. Mark Burns presents "Ebola" by first discussing the history and transmission of Ebola. He then explains the term "person under investigation" as well as how to control the spread of Ebola.
Dr. Anupama Raghuram presents a review of "HIV Pre-Exposure Prophylaxis (PrEP)" by first discussing the HIV global burden of disease and transmission. She then presents the rationale for HIV PrEP as well as the efficacy and indications of HIV PrEP. Finally, she analyzes the initial barriers in prescribing HIV PrEP.
Dr. Anupama Raghuram presents the "Basics of HIV Infection" by first discussing the epidemiology, pathogenesis and transmission of HIV infection. After, she presents the diagnosis, treatment, and prevention of HIV infection.
Dr. Anupama Raghuram discusses "Hepatitis A: An Update in the Context of an Outgoing Multi-state Outbreak" by first reviewing the epidemiology and pathogenesis of hepatits A virus (HAV) infections. She then presents the clinical manifestations and management of HAV infections. After, Dr. Raghuram addresses strategies for prevention of transmission in a variety of clinical settings and finally, reviews data on the ongoing multi-state HAV outbreak in the US.
Dr. Anupama Raghuram discusses OIs in HIV by first reviewing pathogenesis, clinical manifestations, diagnosis, and select opportunistic infections in HIV positive patients. She then discusses challenges in diagnosis and treatment options for select OIs in HIV positive patients
Some items in this lecture may have come from the lecturer’s personal academic files or have been cited in-line or at the end of the lecture. For more information, see our citation page.
Disclaimers
©2015 LouisvilleLectures.org

Audry Hawkins is back to discuss antimicrobial stewardship in pneumonia. She starts with comparing differences in guidelines and recent primary literature on empiric treatment of pneumonia. Hawkins then evaluates appropriate empiric step-down therapy and durations and after, discusses the nuances in guideline recommendations for pneumonia.